Zhejiang Jiuzhou Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yi Jiang Mei

İcra Kurulu Başkanı

CN¥3.6m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	6.2yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	4yrs
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yi Jiang Mei (49 yo)

6.2yrs

Görev süresi

CN¥3,615,000

Tazminat

Mr. Yi Jiang Mei serves as Director at Zhejiang Jiuzhou Pharmaceutical Co., Ltd. since September 06, 2018, serves as its President and served as its Deputy General Manager.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yi Jiang Mei	President & Director	no data	CN¥3.62m	0.11% CN¥ 15.1m
Yujie Sha	Financial Manager	3.5yrs	CN¥1.01m	0.024% CN¥ 3.2m
Huilu Lin	VP, Secretary of the Board of Directors & Director	no data	CN¥1.58m	1.94% CN¥ 258.0m
Yuanqiang Li	Vice President	no data	CN¥1.84m	0.016% CN¥ 2.1m
Nonggang Yang	Vice President	4yrs	CN¥1.35m	0.010% CN¥ 1.4m
Minxia Huang	Vice President	4yrs	CN¥1.05m	0.010% CN¥ 1.4m
Gong Chen	Vice President	no data	CN¥2.27m	0.0013% CN¥ 176.6k

4.0yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 603456 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yi Jiang Mei	President & Director	6.2yrs	CN¥3.62m	0.11% CN¥ 15.1m
Yujie Sha	Financial Manager	3.5yrs	CN¥1.01m	0.024% CN¥ 3.2m
Huilu Lin	VP, Secretary of the Board of Directors & Director	10yrs	CN¥1.58m	1.94% CN¥ 258.0m
Lirong Hua	Chairman	10yrs	CN¥2.51m	3.55% CN¥ 470.9m
Meng Sheng Sun	Chairman of Supervisory Board	10yrs	Veri yok	Veri yok
Xiao Hui Hua	Director	10yrs	Veri yok	Veri yok
Jicheng Li	Independent Director	4yrs	CN¥160.00k	Veri yok
Biao Yu	Independent Director	4yrs	CN¥160.00k	Veri yok
Ming Xu	Director	less than a year	CN¥13.30k	Veri yok
Qi Jiang	Independent Director	1.3yrs	CN¥65.60k	Veri yok

5.1yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 603456 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Zhejiang Jiuzhou Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.39 in 3Q 2023)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 17%

Frontage Laboratories (Shanghai) Co. Ltd. agreed to acquire remaining 25% stake in Frontage Laboratories (Suzhou) Co.,Ltd. from Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) for CNY 19.6 million.

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.38 in 2Q 2023)

Dividend of CN¥0.50 announced

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Now 22% overvalued

Now 21% overvalued

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: CN¥1.16 (vs CN¥1.11 in FY 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş